The team in Brussels is part of the Global Public Affairs business unit within Novartis and is based in the center of Brussels. The team represents the link between the Novartis Group and EU institutions as well as trade associations.
Novartis goes where others don’t
We’re here to listen, to learn and to take action. We’re proud to have launched Novartis EU Connect and reimagine medicine with the EU policy community.
Brussels Team
Rue Belliard 40
B-1040 Brussels
Belgium
Novartis commitment to COVID-19
Learn how Novartis is contributing to the global effort to combat the coronavirus (COVID-19) through research, and philanthropic aid.
Novartis EU priorities
Learn more on our work to run the business smoothly
Accelerate Access
We are committed to work with all stakeholders to develop collaborative and sustainable access solutions that address affordability concerns but more important, ensuring that patients have the right access to the right treatment.
Cancer
Cancer is a policy priority for Europe and a societal issue given its profound effect on patients, caregivers, family, health care systems and society. The EU beating cancer plan shows the strong commitment of the EU.
Data and Digital
We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. New technologies have the potential to improve applications that will improve patients’ lives.
Environmental, social and governance
Very ambitious targets are launched to be a leader in environmental sustainability in the healthcare industry, further strengthening its already ambitious target for carbon neutrality to include its entire supply chain by 2030.
Orphan Medicinal Products & Pediatrics
Our mission is to reimagine medicine to improve and extend people’s lives, including transformative medicines for rare disease patients and children in Europe and around the world.
Security of supply
Working closely with competent authorities to ensure all patients have timely access to high quality treatments and medicines. In order to achieve this policy priorities should be on security of supply, rather than on localization of manufacturing.
4.4bn
Euros of R&D investments in Europe
45 000
Employees in Europe, 10 000 in R&D
80
Sites in Europe, from R&D to manufacturing to commercial
130
Academic and industry alliances in Europe
Trade associations
EFPIA
Stands for European Federation of Pharmaceutical Industries and Associations representing biopharmaceutical industry operating in Europe. EFPIA has a direct membership of 36 national associations and 39 leading pharmaceutical companies.
Eucope
Is Europe's trade body for innovative companies working in the field of pharmaceuticals and medical technologies who are active in research, development of pharmaceuticals, biotechnologies and medical devices.
EuropaBio
The European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. They represent 78 corporate, associate members and bioregions & 15 national biotechnology associations representing over 1800 biotech SMEs.
MedicinesforEurope
Represents the European generic, biosimilar and valued added pharmaceutical industries. Their members’ portfolio covers 80% of therapy areas, and in so doing, safeguards the sustainability of Europe’s healthcare systems for future generations.